Exact Mass: 455.28962520000005

Exact Mass Matches: 455.28962520000005

Found 352 metabolites which its exact mass value is equals to given mass value 455.28962520000005, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

O-[(9Z)-17-Carboxyheptadec-9-enoyl]carnitine

3-{[(9Z)-17-carboxyheptadec-9-enoyl]oxy}-4-(trimethylammonio)butanoic acid

C25H45NO6 (455.324671)

O-[(9Z)-17-Carboxyheptadec-9-enoyl]carnitine is an acylcarnitine. More specifically, it is an octadecenedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. O-[(9Z)-17-Carboxyheptadec-9-enoyl]carnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine O-[(9Z)-17-Carboxyheptadec-9-enoyl]carnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(9E)-Octadec-9-enedioylcarnitine

3-[(17-Carboxyheptadec-9-enoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C25H45NO6 (455.324671)

(9E)-octadec-9-enedioylcarnitine is an acylcarnitine. More specifically, it is an (9E)-octadec-9-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9E)-octadec-9-enedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9E)-octadec-9-enedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(11E)-Octadec-11-enedioylcarnitine

3-[(17-Carboxyheptadec-11-enoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C25H45NO6 (455.324671)

(11E)-octadec-11-enedioylcarnitine is an acylcarnitine. More specifically, it is an (11E)-octadec-11-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (11E)-octadec-11-enedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (11E)-octadec-11-enedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(9S,10E,12Z)-9-Hydroperoxyoctadeca-10,12-dienoylcarnitine

3-[(9-hydroperoxyoctadeca-10,12-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H45NO6 (455.324671)

(9S,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoylcarnitine is an acylcarnitine. More specifically, it is an (9S,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9S,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9S,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(9Z,11E,13S)-13-Hydroperoxyoctadeca-9,11-dienoylcarnitine

3-[(13-hydroperoxyoctadeca-9,11-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H45NO6 (455.324671)

(9Z,11E,13S)-13-hydroperoxyoctadeca-9,11-dienoylcarnitine is an acylcarnitine. More specifically, it is an (9Z,11E,13S)-13-hydroperoxyoctadeca-9,11-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9Z,11E,13S)-13-hydroperoxyoctadeca-9,11-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9Z,11E,13S)-13-hydroperoxyoctadeca-9,11-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(13R)-11alpha-acetoxy-2alpha-hydroxy-13-(R-2-methylbutyryloxy)hetisane|trichodelphinine C

C27H37NO5 (455.26715920000004)

3-demethylmethymycin

C24H41NO7 (455.28828760000005)

puberunine A

C23H37NO8 (455.2519042)

3-demethylneomethymycin

C24H41NO7 (455.28828760000005)

(2S,3R,4R,4aS,4bR,6aS,12bS,12cS,14aS)-4a-demethylpaspaline-3,4,4a-triol

C27H37NO5 (455.26715920000004)

Discarine M|discarine-M

C26H37N3O4 (455.27839220000004)

Phe Tyr Leu

C25H33N3O5 (455.24200880000006)

Leu Tyr Phe

C25H33N3O5 (455.24200880000006)

Ala His Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanamido]hexanoic acid

C19H33N7O6 (455.24921980000005)

Tyr Leu Phe

C25H33N3O5 (455.24200880000006)

Phe Leu Tyr

C25H33N3O5 (455.24200880000006)

Tyr Phe Leu

C25H33N3O5 (455.24200880000006)

1,2,3,4-Tetrahydro-6,7-dimethoxy-1-methylisoquinolinyl-8,12dihydro-5,6-epoxy-2-hydroxyalantolactone

"NCGC00160314-01!1,2,3,4-Tetrahydro-6,7-dimethoxy-1-methylisoquinolinyl-8,12dihydro-5,6-epoxy-2-hydroxyalantolactone"

C27H37NO5 (455.26715920000004)

Ala His Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]hexanamido]-3-hydroxybutanoic acid

C19H33N7O6 (455.24921980000005)

Ala Ile Pro Arg

(2S)-2-{[(2S)-1-[(2S,3S)-2-[(2S)-2-aminopropanamido]-3-methylpentanoyl]pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanoic acid

C20H37N7O5 (455.2856032)

Ala Ile Arg Pro

(2S)-1-[(2S)-2-[(2S,3S)-2-[(2S)-2-aminopropanamido]-3-methylpentanamido]-5-carbamimidamidopentanoyl]pyrrolidine-2-carboxylic acid

C20H37N7O5 (455.2856032)

Ala Lys His Thr

(2S,3R)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanoic acid

C19H33N7O6 (455.24921980000005)

Ala Lys Thr His

(2S)-2-[(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanoic acid

C19H33N7O6 (455.24921980000005)

Ala Leu Pro Arg

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-aminopropanamido]-4-methylpentanoyl]pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanoic acid

C20H37N7O5 (455.2856032)

Ala Leu Arg Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-4-methylpentanamido]-5-carbamimidamidopentanoyl]pyrrolidine-2-carboxylic acid

C20H37N7O5 (455.2856032)

Ala Pro Ile Arg

(2S)-2-[(2S,3S)-2-{[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl]formamido}-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C20H37N7O5 (455.2856032)

Ala Pro Leu Arg

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl]formamido}-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C20H37N7O5 (455.2856032)

Ala Pro Arg Ile

(2S,3S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C20H37N7O5 (455.2856032)

Ala Pro Arg Leu

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C20H37N7O5 (455.2856032)

Ala Arg Ile Pro

(2S)-1-[(2S,3S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanamido]-3-methylpentanoyl]pyrrolidine-2-carboxylic acid

C20H37N7O5 (455.2856032)

Ala Arg Leu Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanamido]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid

C20H37N7O5 (455.2856032)

Ala Arg Pro Ile

(2S,3S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}-3-methylpentanoic acid

C20H37N7O5 (455.2856032)

Ala Arg Pro Leu

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}-4-methylpentanoic acid

C20H37N7O5 (455.2856032)

Ala Thr His Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-aminopropanamido]-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanamido]hexanoic acid

C19H33N7O6 (455.24921980000005)

Ala Thr Lys His

(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-aminopropanamido]-3-hydroxybutanamido]hexanamido]-3-(1H-imidazol-4-yl)propanoic acid

C19H33N7O6 (455.24921980000005)

His Ala Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]propanamido]hexanamido]-3-hydroxybutanoic acid

C19H33N7O6 (455.24921980000005)

His Ala Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]propanamido]-3-hydroxybutanamido]hexanoic acid

C19H33N7O6 (455.24921980000005)

His Lys Ala Thr

(2S,3R)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]hexanamido]propanamido]-3-hydroxybutanoic acid

C19H33N7O6 (455.24921980000005)

His Lys Thr Ala

(2S)-2-[(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]hexanamido]-3-hydroxybutanamido]propanoic acid

C19H33N7O6 (455.24921980000005)

His Thr Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanamido]propanamido]hexanoic acid

C19H33N7O6 (455.24921980000005)

His Thr Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanamido]hexanamido]propanoic acid

C19H33N7O6 (455.24921980000005)

Ile Ala Pro Arg

(2S)-2-{[(2S)-1-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]propanoyl]pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanoic acid

C20H37N7O5 (455.2856032)

Ile Ala Arg Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]propanamido]-5-carbamimidamidopentanoyl]pyrrolidine-2-carboxylic acid

C20H37N7O5 (455.2856032)

Ile Ile Asn Pro

(2S)-1-[(2S)-2-[(2S,3S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylpentanamido]-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid